HCR Wealth Advisors Raises Stock Position in Danaher Co. (NYSE:DHR)

HCR Wealth Advisors grew its holdings in Danaher Co. (NYSE:DHR) by 13.4% during the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 933 shares of the conglomerate’s stock after acquiring an additional 110 shares during the period. HCR Wealth Advisors’ holdings in Danaher were worth $259,000 as of its most recent SEC filing.

A number of other hedge funds have also made changes to their positions in the business. Tsfg LLC grew its holdings in Danaher by 733.3% during the 1st quarter. Tsfg LLC now owns 100 shares of the conglomerate’s stock valued at $25,000 after purchasing an additional 88 shares in the last quarter. CarsonAllaria Wealth Management Ltd. acquired a new stake in Danaher during the 2nd quarter valued at $25,000. nVerses Capital LLC acquired a new stake in Danaher during the 2nd quarter valued at $25,000. Redmont Wealth Advisors LLC acquired a new stake in Danaher during the 1st quarter valued at $30,000. Finally, Richardson Financial Services Inc. acquired a new stake in Danaher during the 4th quarter valued at $42,000. Hedge funds and other institutional investors own 79.05% of the company’s stock.

Insider Activity at Danaher

In related news, SVP Georgeann Couchara sold 952 shares of Danaher stock in a transaction dated Monday, August 26th. The shares were sold at an average price of $268.37, for a total value of $255,488.24. Following the sale, the senior vice president now directly owns 4,212 shares in the company, valued at $1,130,374.44. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. In other Danaher news, SVP Georgeann Couchara sold 952 shares of the business’s stock in a transaction dated Monday, August 26th. The shares were sold at an average price of $268.37, for a total transaction of $255,488.24. Following the sale, the senior vice president now directly owns 4,212 shares in the company, valued at approximately $1,130,374.44. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO Rainer Blair sold 9,007 shares of the business’s stock in a transaction dated Wednesday, July 31st. The stock was sold at an average price of $280.00, for a total transaction of $2,521,960.00. Following the sale, the chief executive officer now owns 97,983 shares in the company, valued at $27,435,240. This trade represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 39,659 shares of company stock worth $11,042,433 in the last ninety days. 11.10% of the stock is owned by insiders.

Wall Street Analysts Forecast Growth

DHR has been the subject of a number of recent analyst reports. Bank of America raised their price target on shares of Danaher from $270.00 to $275.00 and gave the company a “neutral” rating in a report on Wednesday, July 24th. Evercore ISI raised their price objective on shares of Danaher from $275.00 to $278.00 and gave the stock an “outperform” rating in a report on Tuesday, October 1st. Robert W. Baird raised their price objective on shares of Danaher from $271.00 to $278.00 and gave the stock an “outperform” rating in a report on Wednesday, July 24th. Stifel Nicolaus raised their price objective on shares of Danaher from $235.00 to $250.00 and gave the stock a “hold” rating in a report on Wednesday, July 24th. Finally, Royal Bank of Canada reissued an “outperform” rating and set a $300.00 price objective on shares of Danaher in a report on Friday, September 6th. Seven investment analysts have rated the stock with a hold rating and twelve have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $282.12.

Danaher Trading Up 1.5 %

NYSE DHR opened at $270.33 on Friday. Danaher Co. has a one year low of $182.09 and a one year high of $281.70. The company has a 50-day simple moving average of $270.31 and a 200-day simple moving average of $259.20. The company has a debt-to-equity ratio of 0.33, a quick ratio of 1.04 and a current ratio of 1.43. The firm has a market capitalization of $200.23 billion, a PE ratio of 45.82, a price-to-earnings-growth ratio of 4.49 and a beta of 0.83.

Danaher (NYSE:DHR) last issued its quarterly earnings data on Tuesday, July 23rd. The conglomerate reported $1.72 earnings per share for the quarter, beating the consensus estimate of $1.57 by $0.15. The firm had revenue of $5.74 billion for the quarter, compared to the consensus estimate of $5.59 billion. Danaher had a net margin of 16.94% and a return on equity of 11.06%. Danaher’s quarterly revenue was down 2.9% compared to the same quarter last year. During the same period last year, the firm posted $2.05 EPS. On average, equities analysts forecast that Danaher Co. will post 7.59 earnings per share for the current year.

Danaher Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Friday, October 25th. Investors of record on Friday, September 27th will be given a $0.27 dividend. The ex-dividend date of this dividend is Friday, September 27th. This represents a $1.08 annualized dividend and a yield of 0.40%. Danaher’s dividend payout ratio is presently 18.31%.

Danaher Company Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.